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SUMMARY
Developments in acute stroke therapy have followed
advances in the understanding of the evolving pathophysiol-
ogy in both ischaemic stroke and intracerebral haemorrhage
(ICH). In ischaemic stroke, rapid reperfusion of the ischae-
mic penumbra with thrombolysis within 3 h of symptom
onset is of proven benefit, but few patients currently receive
therapy, mainly due to the short-time window and lack of
stroke expertise. In ICH, a recent study indicated that a
haemostatic agent can limit ongoing bleeding and improve
outcomes when administered within 4 h of stroke onset.
These advances in acute stroke therapy underlie the concept
that ‘time is brain’ and that urgent intervention can limit
cerebral damage. Neuroprotective therapy could offer the
prospect of a greater proportion of stroke patients receiving
treatment, potentially before imaging and even in the ambu-
lance setting. Virtually all stroke patients would benefit from
receiving multidisciplinary care in acute stroke units.
Keywords: Ischaemic stroke; emergency; neuroprotection;
multidisciplinary
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INTRODUCTION
Stroke is a medical emergency, with a mortality rate higher than
most forms of cancer. It is the second leading cause of death in
developed countries (1) and is the most common cause of
serious, long-term disability in adults (2). In addition to the
impact on patients and families, there are major economic
consequences (2, 3): the total cost of stroke in the USA is
estimated to exceed US $56 billion in 2005 (4). In addition,
the incidence of stroke is increasing with the ageing of popula-
tions and is therefore a major challenge to health planners (5).
Important evidence-based advances in acute stroke have
included proof of the benefit of organised care in stroke units,
modern brain imaging, thrombolytic therapy, the modest ben-
efit of acute aspirin in ischaemic stroke and the potential use of
haemostatic therapy with recombinant factor VIIa (rFVIIa) in
intracerebral haemorrhage (ICH). Currently, intravenous
recombinant tissue plasminogen activator (rt-PA) is the only
pharmacological treatment licensed for treatment of acute
ischaemic stroke in most Western countries, but the uptake of
rt-PA has been disappointingly low, and >95% of patients with
ischaemic stroke do not receive any specific pharmacological
therapy (6–9). Of particular concern is that, while  15% of
ischaemic stroke patients receive rt-PA in some well-organised
stroke centres (8), <2–3% of patients receive such treatment in
community hospitals (7). Why are the majority of ischaemic
stroke patients unable to access acute therapy? Clearly, a lack of
awareness of the common symptoms of stroke remains a major
educational challenge, and the urgency of stroke treatment is
still poorly appreciated. Despite the proven benefit of stroke
units, the majority of patients in most countries cannot access
specialised stroke care. In this paper, we review current treat-
ment guidelinesand new therapeuticprospects,emphasisingthe
importance of early intervention and the need for a multidisci-
plinary approach to the management of stroke patients.
PATHOPHYSIOLOGY OF ACUTE STROKE POSES
AN EMERGENCY
The two maindevelopmentsunderlyingtherapeuticadvances in
stroke are the delineation of the ischaemic penumbra in ischae-
mic stroke and the observation of haematoma growth in ICH.
Ischaemic Stroke
The severity of an acute ischaemic stroke depends on the degree
of impairment of cerebral blood flow and the time to reperfu-
sion. As the ischaemic process evolves, most commonly due to
thromboembolic arterial occlusion, there is a progressive
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ORIGINAL PAPER doi: 10.1111/j.1368-5031.2006.00873.xdecrease in cerebral blood flow. When this falls from normal
levels of approximately 50 to <10 ml/100 g/min, neuronal cell
death rapidly occurs. However, between the ischaemic core and
the normally perfused brain at the periphery lies the ischaemic
penumbra, a zone of moderately reduced cerebral blood flow,
dependent on the proximal arterial occlusion and collateral
supply (Fig. 1). Within the ischaemic penumbra, the neurones
are hypoxic, functionally inactive, but still viable, and this is the
region targeted by acute stroke therapies. The penumbra is a
dynamic, time-based region in which brain tissue will undergo
necrosis over hours to days due to perfusion failure and a
secondary cascade of damaging biochemical events.
These neurotoxic processes include release of glutamate, activa-
tion of N-methyl-D-aspartate (NMDA) and other cell receptors,
influx of sodium and calcium into cells, release of free-radical
species and, ultimately, cellular destruction. The critical time for
effective reperfusion, based on magnetic resonance-imaging
studies, may be around 4.5 h, with earlier restoration leading to
greater tissue salvage (10). However, the therapeutic time windows
in ischaemia remain uncertain. Later, pathophysiological processes
include inflammatory reactions and free-radical release (11). A
limited therapeutic window of opportunity underlies the concept
that ‘time is brain’, and current approaches to therapy are aimed at
limiting stroke damage and improving functional outcomes.
ICH
More recent studies have shown that ICH is also a dynamic
process and potentially amenable to therapeutic intervention.
A prospective study in ICH showed that 38% of patients
exhibited substantial haematoma growth (greater than one-
third increase in volume) if imaged with computerised tomo-
graphy (CT) within 3 h of onset of stroke and repeated 24 h
later (12) (Fig. 2). Most of this growth (26%) occurred
within 1 h of the first scan. This expansion is probably
due to continued bleeding or re-bleeding. This observation
led to the hypothesis that haemostatic therapy could reduce
the volume of the haematoma and result in improved out-
comes (13).
DIAGNOSIS AND TREATMENT OF ACUTE
ISCHAEMIC STROKE
Successful care of acute stroke patients relies on a four-step
process: (i) prompt recognition and reaction to warning signs;
(ii) immediate use of emergency services; (iii) priority trans-
port with notification of the receiving hospital and (iv) rapid
and accurate diagnosis and intervention at the hospital
(14, 15). This ‘chain of recovery’ has also been described
as a five-stage process, comprising the five Rs of successful
stroke management: recognition (of symptoms), reaction
(emergency services are called), response (medical assessment),
reveal (brain imaging) and Rx (treatment initiation) (16).
Emergency Department Assessment
Once a diagnosis of acute ischaemic stroke is suspected, the
duration since symptom onset should be determined as accu-
ratelyaspossible,astimefromonsetisthesinglemostimportant
determinant of therapeutic options. Patients arriving at hospital
Acute DWI Acute PWI
MRA
Figure 1 Patient with an acute right middle cerebral territory
infarct, demonstrating a large ischaemic penumbra perfusion-
weighted imaging (PWI) (perfusion lesion) > diffusion-weighted
imaging (DWI) (diffusion lesion). The magnetic resonance
angiogram (MRA) shows an occluded right middle cerebral artery.
The penumbra represents threatened tissue, which is a target for
acute stroke therapies such as thrombolysis
Figure 2 Computerised tomography scan of haemorrhagic
transformation
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treatmentwithrt-PA,althougha‘doortoneedletime’ofaround
60 min usually means a hospital arrival time within 2 h for
rt-PA candidates. A treatment algorithm is shown in Fig. 3 (2).
Patients with acute stroke should be investigated with an
emergency CT brain scan, to differentiate ischaemic stroke
from ICH and other pathological processes such as subdural
haematoma, tumour and abscess (2). Other emergency inves-
tigations should include blood glucose, electrolytes, full blood
examination and an electrocardiogram.
Stroke Unit Management
Rapid triage of patients to a stroke unit has been shown to
reduce mortality by  20% (17) and improve functional out-
comes (18), reducing disability and the need for institutional
care compared with treatment in a general medical ward (14).
A stroke unit is a geographically localised treatment facility
involving a multidisciplinary stroke team of medical, nursing
and allied health staff, incorporating best-practice stroke treat-
ment protocols (14, 19, 20). Adherence to guidelines reduces
costs with shorter hospital stays (21). However, access to
stroke unit care remains a problem, even in countries with
well-developed stroke systems (22–25).
Stroke units should use integrated care pathways, shown to
reduce the risk of complications (20). An Australian study
correlated improved outcomes in stroke units compared with
general medical wards with adherence to processes of care
(26). Stroke units can be supervised by a neurologist or a
general physician with stroke training and expertise (27, 28).
Physiological monitoring is an important aspect of stroke
unit management. Hyperglycaemia and fever should
be avoided or treated vigorously, as they are independent
adverse prognostic factors. Most stroke patients are hyperten-
sive on admission, but blood pressure often spontaneously
subsides. The management of acute hypertension is contro-
versial, and randomised clinical trials are being performed to
resolve this uncertainty (29).
Consider IA thrombolysis,
experimental therapy or
empiric anticoagulation
Emergent carotid duplex
High-grade symptomatic
ICA stenosis
Spontaneous
improvement or
resolution of symptoms
Anterior circulation
signs/symptoms
Meets rt-PA
criteria
IV rt-PA per
NINDS protocol 
Antithrombotic therapy
after 24 h; stroke
aetiology evaluation
Vascular surgery
consultation for
possible CEA;
antithrombotic
therapy
SAH
ICH
Neurosurgical
consultation
Hydration with NS;
BP management; treat
elevated glucose,
hyperthermia; consider O2
Consider
neurosurgical
consultation
Time of onset
<3 h
Aspirin; DVT prophylaxis
(if needed); stroke
aetiology evaluation
Antithrombotic therapy;
continue stroke
aetiology evaluation
Hydration with NS;
BP management;
treat elevated glucose,
hyperthermia; consider O2
Blood on CT
(or MRI)
Acute stroke
Yes
Yes Yes
Yes Yes
Yes
No
No
No
No No
No
Figure 3 Algorithm for the management of acute stroke [adapted with permission from Zweifler (2)]. BP, blood pressure, CEA, carotid
endarterectomy, CT, computerised tomography; DVT, deep vein thrombosis; IA, intra-arterial; ICA, internal carotid artery; ICH, intracerebral
haemorrhage, IV, intravenous; MRI, magnetic resonance imaging; NINDS, National Institute of Neurological Disorders and Stroke; NS,
normal saline, rt-PA, recombinant tissue plasminogen activator; SAH, subarachnoid haemorrhage
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include continuous respiratory and cardiac monitoring, fluid
and metabolic replacement (usually intravenous normal
saline), and treatment of hyperglycaemia, seizures and fever.
Prophylaxis for complications such as deep vein thrombosis,
pulmonary embolism, aspiration pneumonia and other infec-
tions are also essential (2). Antiembolic stockings should be
routine, and low-dose heparin/heparinoid is widely recom-
mended (19).
Antiplatelet therapy with aspirin is advised in ischaemic
stroke unless there are contraindications or the patient is
being treated with rt-PA (15). For every 1000 patients treated
with acute aspirin, about nine deaths or nonfatal strokes are
prevented (30, 31). Full anticoagulation is now rarely advo-
cated for most patients in the acute stage, based on results
from a series of negative trials (32). Heparin is frequently
recommended for patients with cerebral vein thrombosis,
arterial dissection and small infarcts, where there is a very
high risk of recurrence. However, it should be emphasised
that adequately powered randomised trials have not been
performed for these indications.
Thrombolysis
Randomised trials of intravenous rt-PA in acute ischaemic
stroke (33–38) and subsequent meta-analyses (32, 39, 40)
have demonstrated an overall benefit for rt-PA treatment,
with a significantly increased probability of excellent recovery
and no increase in mortality rate (32). Overall, the rate of
symptomatic haemorrhagic transformation is increased three-
fold, but this is greatly outweighed by the therapeutic
benefits.
Phase IV studies have subsequently established the relative
safety of rt-PA in appropriate settings (41). The Canadian
Alteplase for Stroke Effectiveness study (42) found that the
rate of symptomatic ICH was low (4.6%) and that the
3-month outcomes were comparable with the National
Institute of Neurological Disorders and Stroke (NINDS)
study data (42, 43). Centres in Germany, the USA and
Australia have published similar findings (44–46). Stroke
guidelines therefore recommend the use of rt-PA in carefully
selected patients within 3 h of the onset of ischaemic stroke
(14, 19).
Optimal treatment outcomes with rt-PA are seen in spe-
cialist stroke centres. Failure to follow the NINDS guidelines
and protocol violations (9) can lead to an increased risk of
haemorrhage and a poorer patient prognosis (47). Hence,
rapid referral of eligible patients to a specialist stroke centre
should be facilitated (48), where there is expertise in neuroi-
maging, stroke evaluation and treatment in a co-ordinated
stroke unit (19).
As mentioned previously, use of rt-PA remains disappoint-
ingly low in most countries. This reflects a number of factors,
including not only the short time window, the relative lack of
expertise and stroke emergency systems, and also professional
pessimism. A vocal minority of emergency department phy-
sicians have argued that additional trial evidence is required
(41, 49), but most experts, including European regulatory
authorities, acknowledge that it is time to explore extended
indications for rt-PA in stroke. For example, the European
licensing approval of rt-PA for acute ischaemic stroke within
3 h of symptom onset after prior exclusion of intracranial
haemorrhage stipulated that a randomised placebo-controlled
trial of alteplase 3–4.5 h after symptom onset (ECASS III) be
undertaken and that every treated patient must be entered
onto a postmarketing registry (SITS-MOST). ECASS-III is a
randomised trial to investigate the safety and efficacy of rt-PA
when administered between 3 and 4 h after symptom onset
(50).
TREATMENT OF ICH
ICH is less common than ischaemic stroke (15 vs. 85% in
most Western populations) but is associated with substantially
worse outcomes. Mortality rates approach 50%, and there is
little effective treatment. A recent trial of more than 1000
patients failed to demonstrate any benefit of early surgery for
supratentorial ICH (51). In this trial, the overall mortality
rate was 64%, and only about 25% of patients had a favour-
able outcome. The role of surgical evacuation is controversial,
although there is a consensus for surgery in selected cases of
cerebellar ICH.
The finding of haematoma growth in a significant propor-
tion of patients with ICH led to the trials of the haemostatic
agent rFVIIa. In a dose-ranging, proof-of-concept trial (52),
haematoma growth was attenuated by nearly 50%. This was
associated with a 40% reduction in mortality in the pooled
rFVIIa-treated groups and improved functional outcomes.
There was a small increase in myocardial and cerebral ischae-
mic events with rFVIIa, but this was substantially outweighed
by the benefits. Based on these results, a second confirmatory
trial is underway.
OPTIMAL PRACTICE AND DRAWBACKS OF
CURRENT PRACTICES
Failure to recognise the stroke symptoms is an important
challenge. Up to 70% of patients having a stroke are unaware
of it, because of lack of knowledge of symptoms or because
they are asleep during onset (53). Furthermore, family mem-
bers and/or carers do not always recognise the common signs
of stroke, compounded by a lack of general awareness of the
urgency of the condition. This underlies the need for public
awareness campaigns to increase knowledge of stroke symp-
toms and facilitate patients being able to access urgent
treatment.
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facilitated (14). Accurate diagnosis remains a challenge in many
settings, emphasising the importance of professional education.
Rapid triage and prioritisation of stroke patients require the
development of effective stroke-management systems (14).
FUTURE OPPORTUNITIES
Despite these important advances in stroke treatment, it is
clear that there is an urgent need for more widely applicable
pharmacological therapy with a wider therapeutic window
and an improved safety profile.
Reperfusion Approaches
Beyond intravenous rt-PA, other reperfusion strategies in
various stages of clinical trial evaluation include intra-arterial
thrombolytic therapy, new thrombolytic agents such as des-
moteplase, intravenous antiplatelet therapies such as abcixi-
mab, enhancement of thrombolysis with ultrasound and
mechanical clot retrieval devices such as the recently licensed
MERCI Retriever device (54) (Table 1). The benefits of
reperfusion therapies always have to be balanced against the
increased risk of bleeding complications. Ultrasound-
enhanced thrombolysis was promising in one study (55) but
associated with increased bleeding complications in another
(56). An abciximab trial has been halted due to a high rate of
bleeding complications.
Ongoing clinical trials using rt-PA are aimed at prolonging
the currently restrictive 3-h window. These include ECASS
III (rt-PA vs. placebo 3–4 h after stroke onset) (50) and IST 3
(rt-PA vs. placebo 0–6 h after onset) (57). To date, there has
only been one Phase III trial of intra-arterial thrombolysis.
The Prolyse in Acute Cerebral Thromboembolism trial used
a 6-h time window and focused on patients with middle
cerebral artery (MCA)-territory infarction (58). The trial
was positive, but a confirmatory trial is needed. Intra-arterial
thrombolytic therapy is used in expert centres in highly
selected patients, such as those with basilar artery thrombosis,
where substantial Phase II evidence suggests a correlation
between recanalisation and reduced mortality (59).
However, one study indicated equally good results from
intravenous thrombolytic therapy (60).
There are also several magnetic resonance imaging-based
trials using combined perfusion-weighted imaging (PWI) and
diffusion-weighted imaging (DWI), aimed at determining
whether PWI > DWI mismatch, as a signature of the ischae-
mic penumbra, can be used to select treatment responders
beyond 3 h (61). Intravenous desmoteplase was shown
to enhance reperfusion with associated clinical benefits up to
9 h in a recent study (62).
Neuroprotective Strategies
Ideally, acute therapy for ischaemic stroke would not require a
preliminary CT scan so that therapy could potentially be
administered by paramedical personnel in the prehospital
setting. A safe therapy would also facilitate treatment outside
of specialist stroke centres. An optimal neuroprotective strat-
egy should be administrable intravenously, have a longer
window of opportunity than rt-PA, be well tolerated and
improve functional recovery after stroke. The proposed sites
of action of various neuroprotective strategies within the
ischaemic cascade are illustrated in Fig. 4.
Table 1 Reperfusion strategies for the treatment of acute ischaemic stroke
Strategy Agent Comments
Antithrombotic agents Heparin Heparin is widely used in acute stroke, but no randomised clinical trials
support its use
Tinzaparin
Low molecular
weight heparin
Ongoing study of eptifibatide in combination with aspirin, tinzaparin and
standard alteplase therapy
Antiplatelet agents Aspirin Two trials showed a small ( 1%) but significant effect with early aspirin
use in acute stroke (30, 31)
Abciximab Ongoing Phase III studies
Thrombolytics rt-PA Approved
Ongoing studies to investigate extension of treatment window to 6 h,
intra-arterial administration and as combination therapy(e.g. with ultrasound)
Pro-urokinase PROACT III trial planned
Desmoteplase Dose-ranging Phase III trial planned
Urokinase MELT ongoing in Japan
Mechanical clot retrieval device MERCI Retriever Licensed
In a study of 141 patients, efficacy appeared similar to that of rt-PA (54)
rt-PA, recombinant tissue plasminogen activator; PROACT, prolyse in acute cerebral thromboembolism; MELT, MCA-Embolism Local fibrinolytic intervention
Trial.
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proved effective in animal models, but have generally failed
translation to the clinical setting. However, the field has been
revitalised with the positive results of the first trial of NXY-
059 in acute ischemic stroke. Possible reasons for the many
failed trials include difficulty with more complex and hetero-
geneous human stroke compared with the animal models,
dosing issues with poor penetration of neuroprotective drugs
into the ischaemic penumbra, relatively long therapeutic time
windows used in many neuroprotective trials, adverse effects,
inadequate sample size and other trial design issues. To
improve the prospects of translational success, the Stroke
Therapy Academic Industry Roundtable (STAIR) devised
recommendations for clinical development of acute ischaemic
stroke therapies. These criteria included human trials of
agents that have been proven effective in more than one
animal model, improved trial design with adequate sample
sizes and valid outcome measures that are easy to measure,
reproducible, valid, clinically meaningful and resistant to bias
(63, 64).
Several novel neuroprotective compounds are currently
in clinical development. These include NXY-059 (free-
radical-trapping agent), DP-b99 (calcium chelator), magne-
sium (NMDA channel blocker) (65), ONO-2506 (astrocyte-
modulating agent) (66), traxoprodil (NR2B-selective
NMDA-receptor antagonist) (67) and citicoline (membrane
stabiliser) (68).
Of these compounds, NXY-059 was the first to meet the
STAIR criteria and is the most advanced in development
(69, 70). NXY-059 is a novel free-radical-trapping neuropro-
tectant that limits infarct size and improves functional
outcomes in animal models (69–71). Preclinical studies
showed that NXY-059 reduces infarct size in both transient
(72, 73) and permanent (73, 74) MCA occlusion (MCAO)
stroke models in the rat. Furthermore, when administered 4 h
after permanent MCAO in a primate model, NXY-059 pro-
duced improvements in motor paresis and spatial neglect
(75).
NXY-059 has been shown to be well tolerated in stroke
patients at doses that are neuroprotective in both transient
and permanent MCAO models in animals (76, 77). A phar-
macokinetic study of NXY-059 in acute stroke patients (78)
showed that an initial loading dose, followed by a mainte-
nance infusion (individualised by creatinine clearance),
resulted in the early achievement of target plasma concentra-
tions. NXY-059 is being evaluated in two Phase III Stroke
Acute Ischaemic NXY-059 Treatment trials, one of which has
been completed. The results of this trial of NXY-059 in 1699
patients showed that administration of this drug within 6
hours of the onset of ischemic stroke significantly improved
the primary outcome, namely disability at 90 days. The drug
also had an excellent safety profile. Although neurological
functioning was not improved using a prespecified measure
of change in the National Institutes of Health Stroke Scale
(NIHSS), there were encouraging trends to benefit in the
proportion of patients with excellent neurological recovery
and in other outcome functional measures. In a further ana-
lysis, co-administration of NXY-059 and tPA was associated
with a reduced rate of hemorrhagic transformation. A second
pivotal trial of NXY-059 is well underway. Confirmation of
the results of the initial trial should lead to availability of a
treatment that could be widely applied and safely used alone or
Acute ischaemic stroke
Reperfusion cascade
Inflammation
Ischaemic cascade
Glutamate release
NMDA/AMPA–receptor activation
Depolarisation
Calcium increase
Free-radical increase Free-radical increase
AMPA
antagonists
GABA mimetics
Calcium antagonists
NMDA antagonists
Ion channel antagonists
Glycine antagonists
Channel blockers
Nitric oxide
Synthesis
inhibitors
Free-radical-
trapping agents
Neuronal cell death
Repair mechanisms
Figure 4 Schematic showing sites of action of neuroprotectants in the ischaemic cascade. AMPA, a-amino-3-hydroxy-methyl-4-isoxazolyl-
propionic acid; GABA, g-amino-butyric acid; NMDA, N-methyl-D-aspartate
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were based on the STAIR criteria (64). In addition, the
Cerebral Hemorrhage and NXY Treatment (CHANT) trial is
a double-blind, randomised trial aimed at assessing the safety
and tolerability of intravenous infusion of NXY-059 in ICH.
ONO-2506 progressed to clinical development after
demonstrating neuroprotective effects in rodent and primate
models. ONO-2506 was shown to reduce infarct expansion
in a rat model up to 48 h after permanent MCAO (80).
When administered 6 h after permanent MCAO in a primate
model (cynomolgus monkeys), ONO-2506 significantly
reduced neurological symptoms up to 14 days after the
onset of ischaemia (81). However, a Phase II study in the
USA involving approximately 1300 patients was recently
halted because of futility in an interim analysis (82). A
Phase II/III study is currently ongoing in Japan.
Although intravenous magnesium sulphate was not effective
within 12 h in a large Phase III trial (83), pilot studies in the
USA have shown the feasibility of an ambulance-based therapy
for stroke (84). A large Phase III trial is now underway with a
2-h time window, involving prehospital therapy (FAST-MAG)
(85). There also remains a possibility that later administration
of magnesium may be of benefit in lacunar stroke (83).
CONCLUSIONS
Stroke is a clinical emergency requiring urgent medical inter-
vention. Thrombolytic therapy with rt-PA is available for the
treatment of acute ischaemic stroke, but its use is currently
suboptimal. Recent advances in the organisation of acute
stroke care, improved understanding of the evolving patho-
physiology of both acute ischaemic stroke and ICH, together
with advances in acute pharmacological therapy including
neuroprotective approaches, are changing the way that acute
stroke is managed around the world. Further advances in drug
therapy are likely to occur in the next few years, with the
potential for prehospital treatment of stroke patients. All of
these treatment advances are based on immediate intervention,
underlining the urgency of stroke recognition and treatment.
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